Is Xanax or Ativan Stronger? Potency Explained

Xanax (alprazolam) is roughly twice as potent as Ativan (lorazepam) on a milligram-for-milligram basis. A clinical study that gave healthy volunteers single oral doses found that 1 mg of alprazolam produced effects comparable to 2 mg of lorazepam. That potency difference sounds dramatic, but it tells you less about real-world strength than you might think, because doctors simply adjust the dose to match. The more meaningful differences between these two drugs lie in how quickly they hit, how fast they wear off, and what happens when you try to stop taking them.

What “Twice as Potent” Actually Means

Potency describes how many milligrams it takes to produce a given effect. When researchers compared single oral doses of alprazolam and lorazepam head-to-head in a randomized study, they used 1 mg of alprazolam against 2 mg of lorazepam and found the effects were clinically equivalent.¹ A separate study described these as “clinically equipotent doses” when comparing both drugs alongside diazepam on performance tasks.²

In practical terms, this means a person prescribed 0.5 mg of Xanax is getting roughly the same anxiety-relieving punch as someone prescribed 1 mg of Ativan. A 1 mg Xanax tablet lines up with a 2 mg Ativan tablet. The numbers on the label differ, but the clinical effect at the standard prescribed dose is similar. This is why asking “which one is stronger?” can be misleading. A doctor prescribing either drug adjusts the dose so the patient gets the level of anxiolytic effect they need. Neither drug is inherently “more powerful” in the way people usually mean when they ask the question. They are simply dosed differently to arrive at the same destination.

Why They Feel Different Despite Similar Strength

If both drugs reach the same endpoint at adjusted doses, why do so many patients swear one feels stronger? The answer has less to do with potency and more to do with how each drug moves through the body. Alprazolam is more lipid-soluble, meaning it crosses into the brain faster after you swallow it. That faster onset creates a more noticeable “kick,” which many people interpret as the drug being stronger. Lorazepam reaches the brain a bit more gradually, so the transition from anxious to calm feels less abrupt.

Alprazolam also tends to leave the brain faster between doses. Its effects rise and fall more sharply over the course of a day, while lorazepam provides a somewhat steadier presence. For someone taking either drug multiple times a day, this difference in the shape of the effect curve matters more than the raw potency number. The rapid rise and fall of alprazolam is a big part of why it feels “stronger” to some users and why it creates certain clinical problems that lorazepam, despite being the same pharmacological class, produces less often or less intensely.

The Interdose Problem With Alprazolam

One of the most clinically important differences between Xanax and Ativan has nothing to do with how well they treat anxiety and everything to do with what happens between doses. Because alprazolam levels in the brain spike and then drop relatively quickly, people on chronic treatment can experience what is called interdose withdrawal or rebound anxiety. Between one dose wearing off and the next one kicking in, anxiety returns, sometimes worse than it was before treatment began.

A review in Psychotherapy and Psychosomatics described this cycle in detail: with a short-half-life agent like alprazolam, rapid onset of both reward and distress can alternate, pushing the person to increase their dose. But the higher dose only intensifies the drop when brain levels fall again, leading to a pattern of escalating use.³ This is a pharmacological trap built into the drug’s profile, not a moral failing on the patient’s part. Lorazepam can produce similar effects but its slightly more gradual decline tends to make the between-dose valleys less steep.

This interdose pattern is one reason addiction specialists have historically viewed alprazolam with more concern than other benzodiazepines. The drug is one of the most frequently prescribed benzodiazepines in the world, widely used for generalized anxiety and panic disorder, yet many addiction medicine physicians consider its unique characteristics a liability that limits its clinical usefulness.⁴ Primary care doctors, on the other hand, often continue prescribing it for longer than guidelines recommend. That tension between specialties has not been fully resolved by clinical data.

Memory and Cognitive Effects at Equivalent Doses

People sometimes worry that the “stronger” drug will impair their thinking more. At equivalent doses, the two drugs affect cognition in very similar ways. A study comparing chronic use of lorazepam 1 mg with alprazolam 0.5 mg (roughly equipotent doses) found no significant difference between them on anterograde memory tasks. Neither drug at those doses impaired immediate recall of word lists, long-term recall of previously memorized material, or hand-eye coordination as measured by standard tests.⁵

Both benzodiazepines do impair memory at higher doses, and both can cause anterograde amnesia, the kind where you have trouble forming new memories after taking the drug. But the point is that at doses producing the same anti-anxiety effect, neither one is meaningfully worse than the other for your thinking. If someone feels foggier on one than the other, it is more likely a dosing issue or individual variation than an inherent property of the molecule.

Withdrawal Severity and Tapering

This is where the real-world differences between these drugs matter most and where the potency conversation takes on practical weight. Both alprazolam and lorazepam are classified as high-potency benzodiazepines, and both have relatively short half-lives. Those two features, high potency and short duration, are the combination most associated with difficult withdrawal.

A 2025 paper in Psychological Medicine reviewed the pharmacological principles behind safe benzodiazepine dose reduction and found that benzodiazepines with shorter elimination half-lives more commonly cause severe withdrawal problems. The paper specifically called out both alprazolam and lorazepam as having short alpha half-lives, the initial rapid drop in blood levels after a dose, which may be even more influential on withdrawal risk than the overall elimination half-life. High-potency drugs like alprazolam, clonazepam, and lorazepam were all associated with more withdrawal difficulty than lower-potency options.⁶

In practice, though, alprazolam consistently earns a worse reputation for withdrawal than lorazepam. Part of the reason goes back to that interdose withdrawal cycle: by the time someone decides to stop alprazolam entirely, their nervous system may already be accustomed to the rapid swings, making the final taper feel especially rough. Clinicians commonly switch patients from alprazolam to a longer-acting benzodiazepine like diazepam before beginning a gradual taper, because diazepam’s slow, steady decline gives the brain a more gentle off-ramp. Lorazepam sometimes requires the same strategy, but anecdotally and in clinical literature, the alprazolam-to-diazepam crossover taper is far more commonly discussed.

Overdose Toxicity

Potency differences take on a different meaning when the topic turns to overdose. Benzodiazepines as a class are relatively safe in overdose when taken alone, especially compared to the barbiturates they replaced. But within the benzodiazepine family, not all members carry the same risk. A study published in the British Journal of Clinical Pharmacology analyzed overdose data and concluded that alprazolam was significantly more toxic than other benzodiazepines in overdose.⁷

A separate analysis calculating the fatal toxicity index, a measure of deaths per defined daily dose, found that alprazolam had a relative death rate roughly six times higher than the average for other sedatives and anxiolytics.⁸ This does not mean alprazolam is six times more dangerous per milligram. The statistic is complicated by the fact that people who take alprazolam may be more likely to combine it with opioids or alcohol, and the drug’s popularity means more of it is circulating. But even accounting for those confounders, the data consistently points to alprazolam carrying a somewhat higher overdose risk than lorazepam and most other benzodiazepines.

The practical implication: if you or someone you know is prescribed either drug, the general safety advice applies to both. Never combine benzodiazepines with opioids, alcohol, or other central nervous system depressants. But the margin for error with alprazolam appears to be narrower.

Who Gets Prescribed Which, and Why

Given that both drugs treat the same conditions at adjusted doses, you might wonder why one exists at all. Each has its niche. Alprazolam became the go-to treatment for panic disorder in the 1980s and early 1990s, partly because its fast onset made it effective at aborting acute panic attacks. It remains one of the most widely prescribed benzodiazepines in the world for that reason, despite the concerns about dependence and withdrawal.⁴

Lorazepam has its own advantages. It is metabolized by a simpler pathway in the liver that does not involve the cytochrome P450 enzyme system to the same degree as alprazolam. That makes lorazepam a safer choice for people with liver disease, older adults whose liver function has declined, or patients taking multiple medications that interact with P450 enzymes. In hospital settings, lorazepam is the more common choice for acute agitation, alcohol withdrawal, and pre-procedural sedation. It is also available as an injection, which alprazolam is not, making it more versatile in emergency situations.

The prescribing decision often comes down to context. For a person whose main complaint is panic attacks that strike suddenly and need to be controlled fast, alprazolam’s rapid onset is an advantage. For someone who needs steady, predictable anxiolytic coverage throughout the day, or who is at higher risk for drug interactions, lorazepam may be a better fit. Neither choice is wrong in the abstract. The “right” one depends on the clinical picture.

The Potency Myth and What People Actually Want to Know

When people search for which drug is “stronger,” they are often really asking one of two different questions. The first is whether switching from one to the other will feel different. The answer is yes, but not because of raw strength. The subjective experience differs mainly because of onset speed and duration, not because one drug produces more anxiolysis per dose when properly adjusted. If your doctor switches you from Xanax 0.5 mg to Ativan 1 mg, the anti-anxiety effect should be comparable. What changes is the timing: when you first feel it, how long it lasts, and how noticeable the transition is when it wears off.

The second question people are often really asking is which drug is more dangerous or more addictive. Here, the evidence tilts toward alprazolam carrying more risk, not because it is inherently a “worse” drug, but because its pharmacokinetic profile, the rapid in and out, creates conditions more favorable to dose escalation, interdose distress, difficult withdrawal, and higher overdose toxicity.³ Lorazepam is not risk-free by any stretch. It is still a high-potency benzodiazepine with real dependence potential. But on a relative scale within the benzodiazepine class, alprazolam has accumulated more red flags.

How Metabolism Creates Individual Variation

The two-to-one potency ratio between alprazolam and lorazepam is a population average, not a universal constant. Individual responses to either drug vary depending on age, liver function, body composition, genetics, and what other medications you are taking. A person with reduced liver enzyme activity may clear alprazolam more slowly, effectively making a low dose last longer and hit harder than expected. Someone whose metabolism runs fast in the other direction might burn through a standard dose and feel it wear off prematurely.

Lorazepam’s simpler metabolic pathway gives it somewhat more predictable behavior across different populations, which is partly why it is favored in geriatric medicine and in patients with compromised liver function. Alprazolam relies more heavily on specific liver enzymes that can be sped up or slowed down by other drugs, grapefruit juice, and genetic variation. If you take a medication that inhibits those enzymes, alprazolam levels in your blood can climb higher than expected, essentially making the drug “stronger” for you than the standard equivalency chart suggests.

This individual variability is worth keeping in mind whenever you see neat equivalency tables online. Those tables are useful starting points for dose conversions, but your body is not a table. Switching between benzodiazepines always requires medical supervision and usually some fine-tuning to get the dose right for the individual.

Extended-Release Alprazolam and How It Changes the Comparison

Alprazolam is available in an extended-release (XR) formulation that changes some of the dynamics described above. The XR version releases the drug more gradually, blunting the sharp peak and smoothing out the curve over the day. This reduces but does not eliminate the interdose dip problem. For people who need alprazolam specifically, perhaps because it works better for their panic disorder than alternatives, the XR version offers a compromise: the same molecule with a less rollercoaster-like delivery.

However, the XR formulation does not change the core potency relationship. One milligram of extended-release alprazolam still roughly equals 2 mg of lorazepam in terms of total anxiolytic effect. What it changes is the timing and subjective experience. Some patients find the XR version less “effective” because they miss the rapid onset that made immediate-release alprazolam feel like it was doing something. That perception is itself revealing: it suggests that part of what people experience as alprazolam’s “strength” is really its speed, not its pharmacological power.

Lorazepam does not have a comparable extended-release form. Its already more moderate onset and offset profile means there has been less clinical demand for one. In a sense, lorazepam naturally sits somewhere between immediate-release and extended-release alprazolam in terms of how the effect unfolds over time, though the comparison is approximate.

Benzodiazepine Equivalency Charts and Their Limits

Equivalency charts circulate widely online and in clinical references. They list rough dose conversions: alprazolam 0.5 mg equals lorazepam 1 mg equals diazepam 5 mg equals clonazepam 0.25 to 0.5 mg, and so on. These charts are genuinely useful for clinicians doing cross-tapers or switching patients between medications, and the alprazolam-to-lorazepam ratio has been validated in controlled studies.¹

But equivalency is measured on a specific axis, usually sedation or anxiolysis. It does not mean the drugs are interchangeable in every respect. Two drugs can be “equivalent” for anxiety relief at their respective doses while differing substantially in muscle relaxant effects, anticonvulsant activity, amnestic properties, and abuse liability. The chart tells you how to match one effect. It says nothing about the full profile of how the drug will feel or behave in your body. Treating the chart as a complete comparison, rather than a single-axis translation tool, is one of the most common misunderstandings in the benzodiazepine conversation.